Schering initiates phase II lung cancer study
The trial is designed to evaluate the efficacy of PTK/ZK (PTK787/ZK 222584) as a second-line monotherapy in patients with stage IIIb/IV non-small cell lung cancer (NSCLC). The trial,
The Liverpool School of Tropical Medicine (LSTM) in the UK has opened a £20m ($23.2m) robotic AI laboratory to test drugs and vaccines against infections and diseases.